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as the direct oral anticoagulants (DOACs), was introduced
in the United States, as an alternative to vitamin K antag-
onists (VKAs), for the prevention of thromboembolic events
in patients with nonvalvular atrial ﬁbrillation. Subsequently
these drugs were also shown to be safe and effective in the
prevention and treatment of venous thromboembolism.1-4
The direct thrombin inhibitor dabigatran etexilate was the
ﬁrst agent to be approved, followed by the factor Xa (FXa)
inhibitors rivaroxaban, apixaban, and edoxaban. These
DOAC agents have demonstrated similar or superior efﬁ-
cacy to that of VKAs such as warfarin for the prevention of
stroke in patients with nonvalvular atrial ﬁbrillation, and
similar efﬁcacy for the treatment of venous thromboembo-
lism in clinical trials.5 The DOACs also offer clear advan-
tages over warfarin, such as ﬁxed dosing, fewer drugedrug
interactions, and administration without the need for routine
monitoring via coagulation tests.6 With all anticoagulant
therapies, bleeding risks are an ongoing safety concern, but
overall risks of major bleeding with DOACs seem to be
similar to or better than that of warfarin.5,7,8 Furthermore,
the risk of intracranial hemorrhage is signiﬁcantly reduced,
and there may be a slightly increased risk of gastrointestinal
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DOACs, the majority of DOAC-associated bleeding com-
plications can be managed simply by withholding the agent
and providing supportive care for the patient.6 Similarly, the
short half-lives of the DOACs facilitate the timing of
elective surgery after the withdrawal of the agent.1-4
However, urgent reversal of the anticoagulant effect of a
DOAC is required in rare clinical situations, such as
uncontrolled or life-threatening bleeding or when an emer-
gency invasive procedure is required.
Until recently, management of such situations was
complicated by the lack of speciﬁc reversal agents. This has
changed, however, with the introduction of DOAC-speciﬁc
reversal agents. The dabigatran-speciﬁc reversal agent
idarucizumab was approved by the U.S. Food and Drug
Administration in October 2015 and by the European
Medicines Agency in November 2015, for use in the rare
instances when the reversal of the anticoagulant effects of
dabigatran is needed (ie, for emergency surgery and urgent
procedures, or if there is life-threatening or uncontrolled
bleeding).9,10 Two other speciﬁc reversal agents,
andexanet alfa (r-Antidote, PRT064445; Portola Pharma-
ceuticals, South San Francisco, Calif) and ciraparantag
(aripazine, PER-977; Perosphere, Danbury, Conn) are
currently in development. Andexanet alfa is an FXa decoy
molecule with no intrinsic coagulation activity that has been
shown to reverse the effects of direct and indirect FXa in-
hibitors in studies involving nonbleeding volunteers.11-13
Ciraparantag is a potential antidote for direct and indirect
FXa inhibitors and direct thrombin inhibitors, as well as
unfractionated heparin and low-molecular-weight heparins
such as enoxaparin, and thus is being developed as a
“universal agent.”14 It is hoped that these agents will
streamline the management of patients who require urgent
reversal of the anticoagulant effects of DOACs in the
emergency settings of life-threatening bleeds, or as in
the case of idarucizumab, both emergency surgery or
life-threatening bleeds.
This special issue of The American Journal of Medicine
provides information and clinical guidance on the rationale
for speciﬁc reversal agents and their appropriate use.-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S32 The American Journal of Medicine, Vol 129, No 11A, November 2016Clinical data on DOAC-associated bleeding from
phase 3 clinical trials and postmarketing trials are reviewed,
as are current strategies for the management and assessment
of bleeding events, perioperative management in the setting
of DOAC therapy, and reinitiation of DOAC therapy after a
bleeding event. Current data relating to the mode of action,
efﬁcacy, and safety of each of the agents are also provided,
alongside a review of the potential place for these agents in
guidelines and hospital protocols.
References
1. Boehringer Ingelheim Pharmaceuticals. Pradaxa (dabigatran etexilate
mesylate) US prescribing information. Available at: http://bidocs.
boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase¼ren
etnt&folderPath¼/Prescribing%20Information/PIs/Pradaxa/Pradaxa.
pdf. Accessed February 9, 2016.
2. Bristol-Myers Squibb. Eliquis (apixaban) prescribing information.
Available at: http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed
February 17, 2016.
3. Daiichi Sankyo. Savaysa (edoxaban) prescribing information. Avail-
able at: http://dsi.com/prescribing-information-portlet/getPIContent?
productName¼Savaysa&inline¼true. Accessed February 17, 2016.
4. Janssen Pharmaceuticals. Xarelto (rivaroxaban) prescribing information.
Available at: www.xareltohcp.com/shared/product/xarelto/prescribing-
information.pdf. Accessed February 17, 2016.
5. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efﬁcacy
and harms of direct oral anticoagulants in the elderly for stroke pre-
vention in atrial ﬁbrillation and secondary prevention of venous
thromboembolism: systematic review and meta-analysis. Circulation.
2015;132:194-204.6. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart
Rhythm Association Practical Guide on the use of non-vitamin K
antagonist anticoagulants in patients with non-valvular atrial ﬁbrilla-
tion. Europace. 2015;17:1467-1507.
7. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular,
bleeding, and mortality risks in elderly Medicare patients treated with
dabigatran or warfarin for nonvalvular atrial ﬁbrillation. Circulation.
2015;131:157-164.
8. Peacock WF, Patel M, Tamayo S, Sicignano N, Hopf K, Yuan Z.
Major bleeding in a post-marketing assessment of 39,052 non-valvular
atrial ﬁbrillation patients on rivaroxaban. Eur Heart J. 2015;36(suppl):
687.
9. Boehringer Ingelheim Pharmaceuticals. Praxbind prescribing infor-
mation. US Food and Drug Administration. Available at: www.
accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. Accessed
October 20, 2015.
10. Boehringer Ingelheim International. Praxbind summary of product char-
acteristics. Available at: www.ema.europa.eu/docs/en_GB/document_
library/EPAR_-_Product_Information/human/003986/WC500197462.pdf.
Accessed December 8, 2015.
11. Lu G, DeGuzman FR, Hollenbach SJ, et al. A speciﬁc antidote for
reversal of anticoagulation by direct and indirect inhibitors of coagu-
lation factor Xa. Nat Med. 2013;19:446-451.
12. Crowther M, Lu G, Conley PB, et al. Reversal of factor Xa inhibitors-
induced anticoagulation in healthy subjects by andexanet alfa. Crit
Care Med. 2014;42:A1469.
13. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the
reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:
2413-2424.
14. Sullivan DW Jr, Gad SC, Laulicht B, Bakhru S, Steiner S.
Nonclinical safety assessment of PER977: a small molecule reversal
agent for new oral anticoagulants and heparins. Int J Toxicol.
2015;34:308-317.
